See more : ALVES KABLO (ALVES.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Corvus Pharmaceuticals, Inc. (CRVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corvus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- madvertise SA (ALMNG.PA) Income Statement Analysis – Financial Results
- Sligro Food Group N.V. (SLIGR.AS) Income Statement Analysis – Financial Results
- Qilian International Holding Group Limited (QLI) Income Statement Analysis – Financial Results
- Haima Automobile Co.,Ltd (000572.SZ) Income Statement Analysis – Financial Results
- China Wafer Level CSP Co., Ltd. (603005.SS) Income Statement Analysis – Financial Results
Corvus Pharmaceuticals, Inc. (CRVS)
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 0.00 |
| Gross Profit | -151.00K | -367.00K | -460.00K | -632.00K | -743.00K | -847.00K | -842.00K | -594.00K | -148.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.53M | 24.47M | 29.12M | 31.83M | 37.98M | 38.59M | 46.31M | 29.36M | 11.35M | 41.46K |
| General & Administrative | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Other Expenses | 0.00 | 587.00K | 235.00K | 37.46M | 0.00 | 0.00 | 0.00 | 0.00 | -17.60M | 0.00 |
| Operating Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Cost & Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Interest Income | 0.00 | 654.00 | 0.00 | 540.00K | 2.18M | 2.28M | 861.00K | 601.00K | 35.00K | 0.00 |
| Interest Expense | 1.58M | 654.00K | 15.00K | 540.00K | 2.18M | 2.28M | 0.00 | 601.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 175.64K |
| EBITDA | -26.88M | -40.94M | -42.78M | -5.36M | -48.85M | -46.09M | -54.82M | -35.78M | -31.19M | 14.64K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -23.41M | -32.57M | -38.63M | -43.76M | -48.85M | -49.22M | -56.52M | -36.98M | -13.77M | -175.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.62M | -8.74M | -4.61M | 37.77M | 2.18M | 2.28M | 861.00K | 601.00K | -17.57M | 0.00 |
| Income Before Tax | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.74M | -5.04M | -1.17M | -2.93M | 2.28M | -842.00K | -594.00K | -35.00K | 0.00 |
| Net Income | -27.03M | -50.05M | -38.20M | -4.82M | -43.75M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| EPS Diluted | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| Weighted Avg Shares Out | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.00K |
| Weighted Avg Shares Out (Dil) | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.28K |
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
What Makes Corvus (CRVS) a New Buy Stock
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2023 Earnings Conference Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Source: https://incomestatements.info
Category: Stock Reports